Aca­dia de­clares ear­ly win on Nu­plazid de­men­tia study, stun­ning an­a­lysts and send­ing shares soar­ing

Aca­dia Phar­ma­ceu­ti­cals — mak­er of the con­tro­ver­sial psy­chosis drug Nu­plazid — is halt­ing a late-stage tri­al in pa­tients with de­men­tia af­ter the com­pa­ny re­port­ed it had ob­tained enough pos­i­tive da­ta at an in­ter­im read­out to make its pitch to the FDA.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.